PROTAC RIPK degrader-2 is primarily used in research focused on targeted protein degradation, particularly in the study of RIPK (Receptor-Interacting Protein Kinase) signaling pathways. Its application is significant in understanding and potentially treating diseases where RIPK proteins play a critical role, such as inflammatory disorders, neurodegenerative diseases, and certain types of cancer. By inducing the degradation of RIPK proteins, this compound helps researchers explore the mechanisms of cell death and inflammation, providing insights into novel therapeutic strategies. It is a valuable tool in preclinical studies for developing treatments that modulate RIPK activity to achieve desired therapeutic outcomes.